Obducat and Kimberly-Clark entered into a Joint Development Agreement in June 2011. In May 2013 Kimberly-Clark placed a purchase order for a Sindre NIL pilot manufacturing line with Obducat.
In November 2013 a Factory Acceptance Test was concluded at Obducat facilities and now the Site Acceptance Test, performed at Kimberly-Clark facilities in the US, has been approved.
The pilot line will be used for production of medical devices being developed by Kimberly-Clark. The FDA approval process is ongoing and provided that the approval can be obtained a ramp into high volume production is targeted.
This is information that Obducat AB (publ) is required to disclose pursuant to the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on January 22, 2014 at 11:00 CET.
For further information contact:
Henri Bergstrand, Chairman: +46 46 10 16 00 or +46 708 88 72 45 Patrik Lundström, CEO: +46 46 10 16 00 or +46 703 27 37 38
About Obducat AB (publ)
Obducat AB is an innovative developer and supplier of technologies, products and processes used for the production and replication of advanced micro and nano structures. Obducat’s products and services serve the demands of companies within the information storage, semiconductor, printed circuit board, and sensor industries. Obducat’s technologies include electron beam and nano imprint technology. Obducat has offices in Sweden and China, with the headquarter located in Lund, Sweden. The Obducat shares are publicly traded on the Swedish NGM stock exchange. Read more at www.obducat.com